212P Real-world Progression-Free Survival 2 with CDK4/6 Inhibitors Plus Endocrine Therapy and Subsequent Line: Results from the Multicenter SISTER Study
ESMO Open(2023)
Key words
CDK4/6 Inhibitors,Metastatic Breast Cancer
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined